The Journal of Allergy and Clinical Immunology
Volume 116, Issue 6 , Pages 1272-1274, December 2005

Expanding the evidence base for the medical treatment of nasal polyposis

  • Michael S. Blaiss, MD

      Affiliations

    • Corresponding Author InformationReprint requests: Michael S. Blaiss, MD, Clinical Professor of Pediatrics and Medicine, University of Tennessee Health Sciences Center College of Medicine, 7205 Wolf River Blvd, Germantown, TN 38138.

From the Departments of Pediatrics and Medicine, University of Tennessee Health Sciences Center College of Medicine

Received 8 September 2005; received in revised form 14 September 2005; accepted 14 September 2005. published online 14 November 2005.

Germantown, Tenn

Key words: Nasal polyposis, intranasal, corticosteroids, polyp, topical, mometasone furoate nasal spray

Abbreviation used: MFNS, Mometasone furoate nasal spray

No abstract is available. To read the body of this article, please view the Full Text online.

 

 Disclosure of potential conflict of interest: M. Blaiss has consultant arrangements with Schering-Plough, HSK, and sanofi-aventis and is on the speakers' bureau for Schering-Plough, GSK, sanofi-aventis, and AstraZeneca.

PII: S0091-6749(05)02057-9

doi:10.1016/j.jaci.2005.09.009

The Journal of Allergy and Clinical Immunology
Volume 116, Issue 6 , Pages 1272-1274, December 2005

Article Tools